Matthew Rossman
Concepts (281)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vasodilation | 23 | 2025 | 521 | 3.620 |
Why?
| | Endothelium, Vascular | 21 | 2026 | 969 | 3.430 |
Why?
| | Aging | 23 | 2026 | 1981 | 2.980 |
Why?
| | Vascular Stiffness | 14 | 2026 | 465 | 2.940 |
Why?
| | Antioxidants | 7 | 2026 | 581 | 2.720 |
Why?
| | Exercise | 24 | 2025 | 2213 | 2.390 |
Why?
| | Brachial Artery | 9 | 2025 | 207 | 2.350 |
Why?
| | Mitochondria | 8 | 2026 | 989 | 2.250 |
Why?
| | Leg | 16 | 2025 | 239 | 2.110 |
Why?
| | Oxidative Stress | 18 | 2026 | 1379 | 2.110 |
Why?
| | Postmenopause | 3 | 2026 | 391 | 1.740 |
Why?
| | Nitric Oxide | 15 | 2025 | 907 | 1.620 |
Why?
| | Cellular Senescence | 8 | 2026 | 229 | 1.480 |
Why?
| | Mitochondria, Muscle | 6 | 2026 | 121 | 1.380 |
Why?
| | Muscle Fatigue | 5 | 2017 | 98 | 1.210 |
Why?
| | Vascular Diseases | 5 | 2023 | 251 | 1.210 |
Why?
| | Blood Vessels | 3 | 2020 | 173 | 1.110 |
Why?
| | Muscle, Skeletal | 18 | 2026 | 1813 | 1.100 |
Why?
| | Pulmonary Ventilation | 2 | 2022 | 84 | 1.090 |
Why?
| | Aorta | 6 | 2026 | 435 | 1.080 |
Why?
| | Cardiovascular Diseases | 8 | 2026 | 2112 | 1.070 |
Why?
| | Endothelial Cells | 10 | 2026 | 874 | 1.050 |
Why?
| | Femoral Artery | 10 | 2025 | 187 | 0.990 |
Why?
| | Ubiquinone | 1 | 2026 | 35 | 0.940 |
Why?
| | Reactive Oxygen Species | 11 | 2025 | 649 | 0.930 |
Why?
| | Exercise Tolerance | 7 | 2026 | 288 | 0.930 |
Why?
| | Regional Blood Flow | 15 | 2025 | 512 | 0.930 |
Why?
| | Flavonols | 4 | 2026 | 26 | 0.890 |
Why?
| | Organophosphorus Compounds | 1 | 2026 | 84 | 0.890 |
Why?
| | Ascorbic Acid | 3 | 2021 | 181 | 0.860 |
Why?
| | Movement | 8 | 2022 | 295 | 0.860 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 5 | 2017 | 1080 | 0.840 |
Why?
| | Doxorubicin | 4 | 2026 | 399 | 0.790 |
Why?
| | NAD | 1 | 2023 | 81 | 0.770 |
Why?
| | Dietary Supplements | 7 | 2026 | 577 | 0.730 |
Why?
| | Aged | 37 | 2026 | 25862 | 0.720 |
Why?
| | Quadriceps Muscle | 7 | 2021 | 117 | 0.710 |
Why?
| | Citrulline | 1 | 2022 | 46 | 0.710 |
Why?
| | Pulse Wave Analysis | 8 | 2026 | 245 | 0.700 |
Why?
| | Healthy Lifestyle | 2 | 2018 | 35 | 0.690 |
Why?
| | Flavonoids | 3 | 2026 | 87 | 0.680 |
Why?
| | Kidney Diseases | 1 | 2025 | 421 | 0.680 |
Why?
| | Sodium Nitrite | 1 | 2021 | 39 | 0.660 |
Why?
| | Sympathetic Nervous System | 5 | 2026 | 178 | 0.650 |
Why?
| | Bronchi | 1 | 2022 | 270 | 0.630 |
Why?
| | Physical Endurance | 3 | 2025 | 281 | 0.620 |
Why?
| | Stroke Volume | 4 | 2019 | 617 | 0.580 |
Why?
| | Anti-Asthmatic Agents | 1 | 2022 | 274 | 0.580 |
Why?
| | Humans | 72 | 2026 | 145077 | 0.540 |
Why?
| | Hand Strength | 5 | 2026 | 143 | 0.530 |
Why?
| | Heating | 1 | 2017 | 18 | 0.520 |
Why?
| | Cross-Over Studies | 4 | 2026 | 601 | 0.520 |
Why?
| | Kidney | 1 | 2025 | 1497 | 0.520 |
Why?
| | Male | 52 | 2026 | 72317 | 0.500 |
Why?
| | Mice, Inbred C57BL | 11 | 2026 | 6068 | 0.490 |
Why?
| | Middle Aged | 25 | 2026 | 36003 | 0.480 |
Why?
| | Muscle Contraction | 7 | 2021 | 432 | 0.480 |
Why?
| | Asthma | 2 | 2022 | 1917 | 0.480 |
Why?
| | Blood Pressure | 8 | 2026 | 1759 | 0.440 |
Why?
| | Fatigue | 2 | 2014 | 361 | 0.430 |
Why?
| | Arteries | 5 | 2024 | 260 | 0.430 |
Why?
| | Female | 36 | 2026 | 78355 | 0.430 |
Why?
| | Young Adult | 23 | 2025 | 14082 | 0.430 |
Why?
| | Antibiotics, Antineoplastic | 2 | 2025 | 141 | 0.430 |
Why?
| | Hyperemia | 5 | 2022 | 49 | 0.420 |
Why?
| | Heart | 1 | 2018 | 635 | 0.410 |
Why?
| | Vasoconstriction | 6 | 2022 | 218 | 0.410 |
Why?
| | Thioctic Acid | 1 | 2013 | 12 | 0.400 |
Why?
| | Mice | 17 | 2026 | 18562 | 0.390 |
Why?
| | Vitamin E | 1 | 2013 | 117 | 0.380 |
Why?
| | Nitrates | 3 | 2022 | 101 | 0.370 |
Why?
| | Smoking Water Pipes | 2 | 2023 | 9 | 0.370 |
Why?
| | Water Pipe Smoking | 2 | 2023 | 9 | 0.370 |
Why?
| | Knee | 1 | 2012 | 74 | 0.350 |
Why?
| | Animals | 21 | 2026 | 38352 | 0.350 |
Why?
| | Oxygen Consumption | 8 | 2025 | 726 | 0.350 |
Why?
| | Age Factors | 6 | 2025 | 3315 | 0.340 |
Why?
| | Adult | 26 | 2026 | 40538 | 0.340 |
Why?
| | Blood Flow Velocity | 6 | 2019 | 414 | 0.330 |
Why?
| | Resistance Training | 2 | 2023 | 181 | 0.330 |
Why?
| | Diet, Western | 2 | 2021 | 86 | 0.320 |
Why?
| | Dementia | 2 | 2025 | 299 | 0.320 |
Why?
| | Healthy Volunteers | 4 | 2021 | 218 | 0.320 |
Why?
| | Aniline Compounds | 3 | 2025 | 119 | 0.320 |
Why?
| | Exercise Test | 3 | 2022 | 622 | 0.310 |
Why?
| | Posture | 5 | 2016 | 197 | 0.280 |
Why?
| | Electromyography | 4 | 2014 | 419 | 0.270 |
Why?
| | Atherosclerosis | 3 | 2018 | 404 | 0.270 |
Why?
| | Caloric Restriction | 2 | 2020 | 131 | 0.270 |
Why?
| | Renal Insufficiency, Chronic | 2 | 2025 | 648 | 0.260 |
Why?
| | Physical Conditioning, Animal | 2 | 2021 | 248 | 0.250 |
Why?
| | Inflammation | 6 | 2024 | 2911 | 0.250 |
Why?
| | Case-Control Studies | 6 | 2026 | 3635 | 0.240 |
Why?
| | Respiratory Function Tests | 2 | 2022 | 572 | 0.240 |
Why?
| | Biomarkers | 4 | 2025 | 4283 | 0.240 |
Why?
| | Motor Activity | 4 | 2024 | 723 | 0.240 |
Why?
| | Chemokine CXCL12 | 1 | 2026 | 89 | 0.230 |
Why?
| | Trastuzumab | 1 | 2026 | 120 | 0.230 |
Why?
| | Feedback, Physiological | 3 | 2014 | 84 | 0.220 |
Why?
| | Respiratory Muscles | 2 | 2023 | 36 | 0.220 |
Why?
| | Premenopause | 1 | 2025 | 123 | 0.210 |
Why?
| | Spermidine | 1 | 2024 | 18 | 0.210 |
Why?
| | Repetitive Sequences, Nucleic Acid | 1 | 2024 | 116 | 0.200 |
Why?
| | Nicotinamide Mononucleotide | 1 | 2023 | 9 | 0.200 |
Why?
| | Arterial Pressure | 5 | 2019 | 135 | 0.200 |
Why?
| | Lipoproteins, LDL | 1 | 2023 | 114 | 0.190 |
Why?
| | Endothelin-1 | 2 | 2016 | 184 | 0.190 |
Why?
| | Acetylcholine | 2 | 2023 | 204 | 0.190 |
Why?
| | Vaping | 1 | 2023 | 66 | 0.190 |
Why?
| | Sex Factors | 2 | 2025 | 2094 | 0.190 |
Why?
| | Inflammation Mediators | 1 | 2025 | 512 | 0.180 |
Why?
| | Social Class | 1 | 2024 | 271 | 0.180 |
Why?
| | Electronic Nicotine Delivery Systems | 1 | 2023 | 109 | 0.180 |
Why?
| | Adolescent | 7 | 2023 | 22453 | 0.180 |
Why?
| | Administration, Oral | 2 | 2015 | 846 | 0.180 |
Why?
| | Hypertension | 2 | 2021 | 1242 | 0.170 |
Why?
| | Spirostans | 1 | 2021 | 4 | 0.170 |
Why?
| | Breathing Exercises | 1 | 2021 | 21 | 0.170 |
Why?
| | Glomerular Filtration Rate | 1 | 2025 | 753 | 0.170 |
Why?
| | Inhalation | 1 | 2021 | 29 | 0.170 |
Why?
| | Treatment Outcome | 4 | 2022 | 11612 | 0.170 |
Why?
| | Cardiovascular System | 3 | 2020 | 140 | 0.170 |
Why?
| | Hypotension | 1 | 2022 | 127 | 0.170 |
Why?
| | Cancer Survivors | 1 | 2026 | 326 | 0.160 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2021 | 108 | 0.160 |
Why?
| | Double-Blind Method | 3 | 2023 | 2032 | 0.160 |
Why?
| | Pressoreceptors | 1 | 2019 | 19 | 0.150 |
Why?
| | Cardiovascular Abnormalities | 1 | 2019 | 15 | 0.150 |
Why?
| | Cells, Cultured | 2 | 2025 | 4178 | 0.150 |
Why?
| | Cognitive Dysfunction | 1 | 2025 | 454 | 0.150 |
Why?
| | Glucose Intolerance | 1 | 2021 | 145 | 0.150 |
Why?
| | Supine Position | 2 | 2016 | 38 | 0.150 |
Why?
| | Models, Animal | 1 | 2021 | 395 | 0.150 |
Why?
| | Receptors, Adrenergic, beta-1 | 1 | 2019 | 23 | 0.150 |
Why?
| | DNA Methylation | 1 | 2024 | 682 | 0.140 |
Why?
| | Coronary Circulation | 1 | 2019 | 135 | 0.140 |
Why?
| | Electron Transport | 1 | 2018 | 118 | 0.140 |
Why?
| | Athletes | 1 | 2022 | 417 | 0.140 |
Why?
| | Peptides, Cyclic | 3 | 2016 | 276 | 0.140 |
Why?
| | Carotid Arteries | 3 | 2025 | 203 | 0.140 |
Why?
| | Hemodynamics | 6 | 2023 | 1120 | 0.140 |
Why?
| | Fasting | 1 | 2020 | 282 | 0.140 |
Why?
| | Oncogene Protein p21(ras) | 1 | 2017 | 15 | 0.130 |
Why?
| | Endothelin Receptor Antagonists | 2 | 2016 | 62 | 0.130 |
Why?
| | Energy Metabolism | 2 | 2021 | 946 | 0.130 |
Why?
| | Heart Rate | 6 | 2023 | 848 | 0.130 |
Why?
| | Habits | 1 | 2017 | 52 | 0.130 |
Why?
| | Drug Monitoring | 1 | 2021 | 396 | 0.130 |
Why?
| | Muscle Fibers, Skeletal | 1 | 2018 | 215 | 0.130 |
Why?
| | Coronary Vessels | 1 | 2019 | 250 | 0.130 |
Why?
| | Bicycling | 2 | 2021 | 120 | 0.130 |
Why?
| | Sulfonamides | 3 | 2025 | 581 | 0.120 |
Why?
| | Congresses as Topic | 1 | 2018 | 225 | 0.120 |
Why?
| | Primary Prevention | 1 | 2018 | 197 | 0.120 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2026 | 1968 | 0.120 |
Why?
| | Ventricular Function, Left | 1 | 2019 | 522 | 0.110 |
Why?
| | Cardiac Catheterization | 1 | 2019 | 531 | 0.110 |
Why?
| | Cardiovascular Physiological Phenomena | 1 | 2015 | 48 | 0.110 |
Why?
| | Reflex | 1 | 2015 | 71 | 0.110 |
Why?
| | Autonomic Nervous System | 1 | 2015 | 79 | 0.110 |
Why?
| | Reproducibility of Results | 3 | 2022 | 3414 | 0.110 |
Why?
| | Metabolomics | 1 | 2021 | 733 | 0.110 |
Why?
| | Life Style | 1 | 2017 | 486 | 0.110 |
Why?
| | Cell Respiration | 3 | 2021 | 107 | 0.110 |
Why?
| | Maximal Midexpiratory Flow Rate | 1 | 2014 | 5 | 0.110 |
Why?
| | Peak Expiratory Flow Rate | 1 | 2014 | 25 | 0.110 |
Why?
| | Pyramidal Tracts | 1 | 2014 | 30 | 0.110 |
Why?
| | Muscle Strength | 3 | 2023 | 337 | 0.110 |
Why?
| | omega-N-Methylarginine | 4 | 2015 | 29 | 0.110 |
Why?
| | Bronchoconstriction | 1 | 2014 | 29 | 0.110 |
Why?
| | Adrenergic beta-2 Receptor Agonists | 1 | 2014 | 28 | 0.100 |
Why?
| | Ultrasonography, Doppler | 4 | 2016 | 126 | 0.100 |
Why?
| | Receptors, Opioid, mu | 1 | 2014 | 68 | 0.100 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2017 | 374 | 0.100 |
Why?
| | Shear Strength | 1 | 2014 | 73 | 0.100 |
Why?
| | Extremities | 1 | 2014 | 142 | 0.100 |
Why?
| | Cardiac Output | 4 | 2015 | 179 | 0.100 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2017 | 544 | 0.100 |
Why?
| | Vital Capacity | 1 | 2014 | 312 | 0.100 |
Why?
| | Muscle, Smooth, Vascular | 1 | 2016 | 451 | 0.100 |
Why?
| | Electron Spin Resonance Spectroscopy | 1 | 2013 | 98 | 0.100 |
Why?
| | Bronchodilator Agents | 1 | 2014 | 194 | 0.100 |
Why?
| | Free Radicals | 1 | 2013 | 107 | 0.100 |
Why?
| | Forced Expiratory Volume | 1 | 2014 | 493 | 0.090 |
Why?
| | Breast Neoplasms | 1 | 2026 | 2520 | 0.090 |
Why?
| | Recovery of Function | 1 | 2017 | 704 | 0.090 |
Why?
| | Coronary Artery Disease | 1 | 2019 | 726 | 0.090 |
Why?
| | Single-Blind Method | 1 | 2013 | 310 | 0.090 |
Why?
| | Fentanyl | 3 | 2021 | 127 | 0.090 |
Why?
| | Drug Combinations | 1 | 2013 | 381 | 0.090 |
Why?
| | Central Nervous System | 1 | 2014 | 282 | 0.090 |
Why?
| | Drug Administration Schedule | 1 | 2013 | 779 | 0.090 |
Why?
| | Aged, 80 and over | 1 | 2023 | 8200 | 0.080 |
Why?
| | Motor Neurons | 1 | 2013 | 237 | 0.080 |
Why?
| | Spinal Cord | 1 | 2013 | 381 | 0.080 |
Why?
| | Knee Joint | 1 | 2014 | 434 | 0.080 |
Why?
| | Sepsis | 1 | 2016 | 641 | 0.080 |
Why?
| | Follow-Up Studies | 1 | 2018 | 5367 | 0.070 |
Why?
| | Biological Availability | 2 | 2021 | 141 | 0.070 |
Why?
| | Heart Failure | 1 | 2019 | 2181 | 0.060 |
Why?
| | Arterioles | 1 | 2025 | 56 | 0.060 |
Why?
| | Risk Factors | 3 | 2025 | 10700 | 0.060 |
Why?
| | Popliteal Artery | 1 | 2025 | 62 | 0.060 |
Why?
| | Photoplethysmography | 2 | 2016 | 19 | 0.050 |
Why?
| | Fingers | 2 | 2016 | 107 | 0.050 |
Why?
| | Infusions, Intra-Arterial | 2 | 2015 | 62 | 0.050 |
Why?
| | Nitric Oxide Synthase | 2 | 2015 | 240 | 0.050 |
Why?
| | Respiratory Therapy | 1 | 2023 | 25 | 0.050 |
Why?
| | Elastic Modulus | 1 | 2024 | 124 | 0.050 |
Why?
| | Nitric Oxide Synthase Type III | 2 | 2016 | 207 | 0.050 |
Why?
| | Forearm | 1 | 2023 | 139 | 0.050 |
Why?
| | Hypercapnia | 1 | 2023 | 53 | 0.050 |
Why?
| | Time Factors | 3 | 2021 | 7120 | 0.050 |
Why?
| | Lower Extremity | 2 | 2019 | 447 | 0.050 |
Why?
| | Muscles | 1 | 2023 | 334 | 0.050 |
Why?
| | Carbon Dioxide | 1 | 2023 | 243 | 0.040 |
Why?
| | Injections, Spinal | 1 | 2021 | 119 | 0.040 |
Why?
| | Blood Circulation | 1 | 2021 | 44 | 0.040 |
Why?
| | Nicotine | 1 | 2023 | 331 | 0.040 |
Why?
| | Neurons, Afferent | 1 | 2021 | 102 | 0.040 |
Why?
| | Random Allocation | 1 | 2021 | 366 | 0.040 |
Why?
| | Mouth | 1 | 2021 | 91 | 0.040 |
Why?
| | Cerebrovascular Circulation | 1 | 2023 | 277 | 0.040 |
Why?
| | Analgesics, Opioid | 2 | 2021 | 1138 | 0.040 |
Why?
| | Social Determinants of Health | 1 | 2024 | 301 | 0.040 |
Why?
| | Enzyme Inhibitors | 2 | 2015 | 832 | 0.040 |
Why?
| | Cross-Sectional Studies | 2 | 2025 | 5832 | 0.040 |
Why?
| | Interleukin-6 | 1 | 2024 | 791 | 0.040 |
Why?
| | Infusions, Intralesional | 1 | 2019 | 1 | 0.040 |
Why?
| | Diet, High-Fat | 1 | 2021 | 262 | 0.040 |
Why?
| | Adrenergic Antagonists | 1 | 2019 | 5 | 0.040 |
Why?
| | Epigenesis, Genetic | 1 | 2024 | 688 | 0.040 |
Why?
| | Risk Assessment | 2 | 2019 | 3582 | 0.040 |
Why?
| | Blood Pressure Determination | 1 | 2019 | 141 | 0.040 |
Why?
| | Retrospective Studies | 1 | 2016 | 16954 | 0.030 |
Why?
| | Reference Values | 1 | 2019 | 807 | 0.030 |
Why?
| | Immunity, Innate | 1 | 2024 | 856 | 0.030 |
Why?
| | Oxidative Phosphorylation | 1 | 2018 | 211 | 0.030 |
Why?
| | Oxygen | 1 | 2022 | 1003 | 0.030 |
Why?
| | ROC Curve | 1 | 2019 | 610 | 0.030 |
Why?
| | Homeostasis | 1 | 2021 | 644 | 0.030 |
Why?
| | Energy Intake | 1 | 2020 | 505 | 0.030 |
Why?
| | Adipose Tissue | 1 | 2021 | 660 | 0.030 |
Why?
| | Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2016 | 40 | 0.030 |
Why?
| | Electron Transport Complex IV | 1 | 2016 | 62 | 0.030 |
Why?
| | Isocitrate Dehydrogenase | 1 | 2016 | 70 | 0.030 |
Why?
| | Program Development | 1 | 2018 | 371 | 0.030 |
Why?
| | Electron Transport Complex II | 1 | 2015 | 28 | 0.030 |
Why?
| | Electron Transport Complex I | 1 | 2015 | 42 | 0.030 |
Why?
| | Biopsy | 1 | 2018 | 1071 | 0.030 |
Why?
| | Afferent Pathways | 1 | 2014 | 46 | 0.030 |
Why?
| | Disease Models, Animal | 1 | 2025 | 4605 | 0.030 |
Why?
| | Evoked Potentials, Motor | 1 | 2014 | 50 | 0.030 |
Why?
| | Pilot Projects | 1 | 2020 | 1873 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2019 | 2105 | 0.020 |
Why?
| | Electromagnetic Fields | 1 | 2013 | 38 | 0.020 |
Why?
| | Amino Acids, Branched-Chain | 1 | 2013 | 39 | 0.020 |
Why?
| | Program Evaluation | 1 | 2018 | 962 | 0.020 |
Why?
| | Pulmonary Gas Exchange | 1 | 2013 | 119 | 0.020 |
Why?
| | Physical Exertion | 1 | 2014 | 211 | 0.020 |
Why?
| | Endothelin A Receptor Antagonists | 1 | 2012 | 26 | 0.020 |
Why?
| | Microbiota | 1 | 2021 | 785 | 0.020 |
Why?
| | Femoral Vein | 1 | 2012 | 38 | 0.020 |
Why?
| | Receptor, Endothelin A | 1 | 2012 | 63 | 0.020 |
Why?
| | Exercise Therapy | 1 | 2017 | 475 | 0.020 |
Why?
| | Tryptophan | 1 | 2013 | 180 | 0.020 |
Why?
| | Stress, Mechanical | 1 | 2014 | 502 | 0.020 |
Why?
| | Vascular Resistance | 1 | 2012 | 366 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2944 | 0.020 |
Why?
| | Catheterization, Peripheral | 1 | 2012 | 116 | 0.020 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2012 | 564 | 0.020 |
Why?
| | Colorado | 1 | 2021 | 4608 | 0.020 |
Why?
| | Lactic Acid | 1 | 2012 | 305 | 0.020 |
Why?
| | Ultrasonography | 1 | 2015 | 766 | 0.020 |
Why?
| | Lipids | 1 | 2014 | 701 | 0.020 |
Why?
| | Prognosis | 1 | 2018 | 4260 | 0.020 |
Why?
| | Cohort Studies | 1 | 2019 | 5930 | 0.020 |
Why?
| | Transcription Factors | 1 | 2016 | 1742 | 0.020 |
Why?
| | Obesity | 1 | 2021 | 3113 | 0.020 |
Why?
| | Prospective Studies | 1 | 2019 | 7982 | 0.020 |
Why?
| | Phenotype | 1 | 2014 | 3202 | 0.010 |
Why?
|
|
Rossman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|